Key clinical point: Elderly and/or comorbid patients with r/r aggressive large B-cell NHL, ineligible for high-dose chemotherapy and HSCT, can receive liso-cel with safety and efficacy.
Major finding: At a median follow-up of 3.5 months, the overall response rate was 80% (95% confidence interval, 59–93; n=20); 48% of patients (n=12) achieved complete response.
Study details: Open-label, phase 2 PILOT study is the first to assess the safety and efficacy of liso-cel as second-line therapy in transplant noneligible patients
Disclosures: The abstract contained no conflict information.
Ghosh N et al. European Hematology Association virtual annual meeting. 2020; Abstract S244.